Glioblastoma — frontier options in Alabama
18 open options
- TRIALPHASE2RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Temozolomide · Neratinib · QBS10072S — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE2RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Fluciclovine F18 · Gadolinium-Chelate — 18 sites
- TRIALNARECRUITING
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Receive technology-based supportive cancer care · Receive redesigned team-based supportive cancer care — 17 sites
- TRIALPHASE1RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
G207 — 3 sites
- TRIALPHASE2RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
silevertinib in combination with temozolomide · temozolomide (TMZ) — 25 sites
- TRIALEARLY_PHASE1RECRUITING
Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI — 2 sites
- TRIALPHASE1RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Eflornithine (Dose Level 1) · Eflornithine (Dose Level 2) · Eflornithine (Dose Level -1) — 8 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE1RECRUITING
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
TheraSphere GBM — 9 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
[18F]FMISO-PET with contrast-enhanced MRI — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE1RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
PF-07799544 · PF-07799933 — 83 sites
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 57 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Pembrolizumab and M032 (NSC 733972)
M032 · Pembrolizumab — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
mirdametinib with radiation · mirdametinib — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.